keyword
MENU ▼
Read by QxMD icon Read
search

Le prade

keyword
https://www.readbyqxmd.com/read/27678008/major-prognostic-value-of-complex-karyotype-in-addition-to-tp53-and-ighv-mutational-status-in-first-line-chronic-lymphocytic-leukemia
#1
Yannick Le Bris, Stéphanie Struski, Romain Guièze, Caroline Rouvellat, Naïs Prade, Xavier Troussard, Olivier Tournilhac, Marie C Béné, Eric Delabesse, Loïc Ysebaert
Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder of remarkable heterogeneity as demonstrated by cytogenetics and molecular analyses. Complex karyotype (CK), TP53 deletions and/or mutations (TP53 disruption), IGVH mutational status, and, more recently, recurrent somatic mutations have been identified as prognostic markers in CLL. On a cohort of 110 patients with CLL treated with first-line fludarabin, cyclophosphamide, and rituximab treatment compared with 33 untreated (watch and wait) patients with CLL, we report more frequent complex karyotypes (34 vs 15%; P = ...
September 28, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27316915/french-intensive-care-society-international-congress-r%C3%A3-animation-2016
#2
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Annals of Intensive Care
https://www.readbyqxmd.com/read/22883640/french-ent-society-sforl-practice-guidelines-for-lymph-node-management-in-adult-differentiated-thyroid-carcinoma
#3
B Guerrier, J P Berthet, C Cartier, D Dehesdin, A Edet-Sanson, G Le Clech, R Garrel, R Kania, M Makeieff, C Page, S Poirée, G Potard, J M Prades, C Righini, F Roussel, M E Toubert
No abstract text is available yet for this article.
August 2012: European Annals of Otorhinolaryngology, Head and Neck Diseases
https://www.readbyqxmd.com/read/20506527/safety-and-efficacy-of-rituximab-in-systemic-lupus-erythematosus-results-from-136-patients-from-the-french-autoimmunity-and-rituximab-registry
#4
Benjamin Terrier, Zahir Amoura, Philippe Ravaud, Eric Hachulla, Romain Jouenne, Bernard Combe, Christine Bonnet, Patrice Cacoub, Alain Cantagrel, Michel de Bandt, Olivier Fain, Bruno Fautrel, Philippe Gaudin, Bertrand Godeau, Jean-Robert Harlé, Arnaud Hot, Jean-Emmanuel Kahn, Olivier Lambotte, Claire Larroche, Jean Léone, Olivier Meyer, Béatrice Pallot-Prades, Edouard Pertuiset, Pierre Quartier, Thierry Schaerverbeke, Jean Sibilia, Alexandre Somogyi, Martin Soubrier, Eric Vignon, Brigitte Bader-Meunier, Xavier Mariette, Jacques-Eric Gottenberg
OBJECTIVE: A number of open-label studies have suggested the potential benefit of rituximab (RTX) in systemic lupus erythematosus (SLE). However, in 2 recent randomized controlled trials (RCTs) of RTX, the primary end points were not met. We undertook this study to evaluate the safety and efficacy of RTX in off-trial patients with SLE seen in regular clinical practice. METHODS: We analyzed prospective data from the French AutoImmunity and Rituximab (AIR) registry, which includes data on patients with autoimmune disorders treated with RTX...
August 2010: Arthritis and Rheumatism
https://www.readbyqxmd.com/read/20149709/longitudinal-myelitis-in-a-patient-with-systemic-lupus-erythematosus
#5
Aurélie Richard Mornas, Thierry Thomas, Béatrice Pallot Prades, Florence Chopin, Delphine Raoux
Longitudinal myelitis is an exceedingly rare complication of systemic lupus erythematosus (SLE), of which only 11 cases have been published so far. We report a case in a 65-year-old woman in whom spinal cord dysfunction developed over several weeks, resulting in tetraparesis. She had a known history of SLE with a circulating anticoagulant. Magnetic resonance imaging of the spine and a stereotactic biopsy of a brain lesion established the diagnosis of SLE-related longitudinal myelitis. High-dose glucocorticoid therapy had started to bring about an improvement when she experienced a series of complications that were eventually fatal...
March 2010: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/7620339/melanoma-arising-de-novo-in-childhood-experience-of-the-gustave-roussy-institute
#6
E Lartigau, A Spatz, M F Avril, C Bailly, J Lemerle, M J Terrier-Lacombe, A Margulis, M Prade
Between January 1956 and December 1990, 17 patients younger than 17 years with available pathological screens of de novo cutaneous melanoma, and with no other risk factors (xeroderma pigmentosum, giant congenital naevi, congenital melanoma or a proven family history of dysplastic naevus syndrome) were seen at the Gustave-Roussy Institute. The median age was 9 years and 9 months (range 2 years and 3 months-16 years and 9 months). The primary disease was located in the lower extremities in 10 cases, the trunk in five cases, and the upper extremities or head and neck in one case...
April 1995: Melanoma Research
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"